European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
出版年份 2019 全文链接
标题
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
作者
关键词
Migraine, Chronic migraine, Prevention, Erenumab, Fremanezumab, Galcazenumab, Eptinezumab, Calcitonin gene-related peptide
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 20, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-16
DOI
10.1186/s10194-018-0955-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials
- (2018) Rashmi B Halker Singh et al. CEPHALALGIA
- Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
- (2018) Tina Marie Myers Oakes et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
- (2018) Christophe Depre et al. HEADACHE
- A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine
- (2018) Uwe Reuter HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- Migraine is associated with high brain 5-HT levels as indexed by 5-HT4 receptor binding
- (2018) Marie Deen et al. CEPHALALGIA
- Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
- (2018) Dawn C Buse et al. CEPHALALGIA
- Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
- (2018) David W. Ayer et al. HEADACHE
- Fremanezumab for preventive treatment of migraine
- (2018) Juliana VanderPluym et al. NEUROLOGY
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
- (2018) Russell Nichols et al. HEADACHE
- 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
- (2018) Noah Rosen et al. HEADACHE
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
- (2018) Janet H Ford et al. Patient Preference and Adherence
- Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines
- (2017) Joshua M. Cohen et al. HEADACHE
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Erenumab (AMG 334) in episodic migraine
- (2017) Messoud Ashina et al. NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- TEV-48125 for the preventive treatment of chronic migraine
- (2016) Marcelo E. Bigal et al. NEUROLOGY
- Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?
- (2015) JA Pijpers et al. CEPHALALGIA
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
- (2013) Andrew M. Blumenfeld et al. HEADACHE
- A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina
- (2012) B R Chaitman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- Adherence with Migraine Prophylaxis in Clinical Practice
- (2012) Ariel Berger et al. Pain Practice
- Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations
- (2011) Elizabeth W. Loder et al. HEADACHE
- GRADE guidelines: 9. Rating up the quality of evidence
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Migraine prevalence by age and sex in the United States: A life-span study
- (2010) TW Victor et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
- Prevalence of headache in Europe: a review for the Eurolight project
- (2010) Lars Jacob Stovner et al. JOURNAL OF HEADACHE AND PAIN
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta-Analytic Comparison of Topiramate-Related Adverse Drug Reactions in Epilepsy and Migraine
- (2008) J Luykx et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment
- (2008) M. E. Bigal et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now